Cardiff Oncology, Inc.

NASDAQ:CRDF

Biotechnology

Healthcare
$0.84 +2.12%

+$0.03 today

Market cap
$65.27M
Beta
1.38
P/E (TTM)
-1.8
EPS (TTM)
-$0.65
52W Low $1.16High $4.56

Volume 0.86M

Average 1.05M

Returns on capital

Cardiff Oncology, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-101.0%

avg -119.3%

ROIC

-105.9%

avg -94.3%

ROA

-74.1%

avg -73.6%

Analysis

ROA is currently the strongest return metric at -74.1% versus its period average of -73.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Tod Smeal

Chief Scientific OfficerUSD 2.69M611.28M1.87%

Josh Muntner

Chief Financial OfficerUSD 674.75K57——

Roger Sidhu

Chief Medical OfficerUSD 553K50600.00K0.88%

Mani Mohindru

President, CEO & DirectorUSD 77K5434.36K0.05%

Leila Alland

Interim Chief Medical Officer—640<0.01%

Ajay Aggarwal

Chief Operating Officer——0<0.01%

Brigitte Lindsay

Chief Accounting Officer—57——

Elizabeth Anderson

Vice President of Finance & Administration————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 23, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

6

$2.08M

Sells

0

$0.00

Net Transaction Value

+$2.08M

Net buying

Most Active

PACE GARY W

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jul 14, 26

PACE GARY W

Direct

Buy$1M
Jul 14, 26

PACE GARY W

Direct

Buy$914.1K
Jul 14, 26

Mohindru Mani

Direct

Buy$50K
Jul 14, 26

Mohindru Mani

Direct

Buy$45.7K
Jun 18, 26

Mohindru Mani

Direct

Buy$29.9K
Jun 18, 26

PACE GARY W

Direct

Buy$36.6K

Summary

Insiders reported 6 buys worth $2.08M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $2.08M. PACE GARY W was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+15.4%
+249.6% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at +15.4% over three years. Forward estimates point to Revenue at +249.6% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Cardiff Oncology, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CRDF's management, answered from reported figures.

Who manages CRDF?

Cardiff Oncology, Inc. (CRDF) lists 8 active executives. The top listed executive is Leila Alland, Interim Chief Medical Officer.

Are CRDF insiders buying or selling?

Recent insider activity shows net buying of $38.19M.